Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: Al's Fun who wrote (46)	10/27/1999 12:02:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 2355

MYGN traded a whopping 18,000+ shares on news that it sold $10,000,000 in equity to Schering and a Swiss investment company. In addition, it announced that they expanded the Schering agreement(after 1 year) to include cardiovascular, as well as cancer research. In the original agreement, MYGN retained 50/50 profit rights for North America- which I assume will continue in the new arrangement. With the establishment of Myriad Pharmaceutical, this should allay some of the analyst fears regarding an INCY style business model. With a market cap of $175 million, it continues to look appealing. I have to admit that I'm surprised at the lack of analyst recognition in '99. Shhh appears to be the word on Wall Street.